Seeking Alpha

The FDA has approved ImmunoGen's (IMGN) breast cancer drug TDM1, now called Kadcyla. The...

The FDA has approved ImmunoGen's (IMGN) breast cancer drug TDM1, now called Kadcyla. The approval triggers a $10.5M milestone payment to ImmunoGen, with royalties from sales to follow. Shares are halted. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector